Innovation-focused guru increases exposure to SPACs, pharma and tech stocks, trims CRISPR Therapeutics stake. : Catherine Wood (Trades, Portfolio) disclosed last week her firm, ARK Investment PZN Management, made a number of changes to its portfolio in August. Wood, who is the founder, chief investment officer and CEO of the New York-based firm, has made a name for herself through investing in “disruptive innovation” stocks. Implementing an iterative process that combines top-down and bottom-up research, ARK Investment seeks to invest in companies that may benefit from cross-sector innovations like artificial intelligence, robotics, energy storage, DNA sequencing and blockchain technology.